AUTO-3 is under clinical development by Autolus Therapeutics and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase II drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AUTO-3’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AUTO-3 overview

AUTO-3 is under development for the treatment of primary mediastinal large B cell lymphoma, relapsed or refractory B-cell acute lymphoblastic leukemia in pediatrics and young adults and diffuse large B-cell lymphoma. It is administered as an intravenous infusion. It consists of patient’s own genetically modified T cells by CAR gene, that selective target and destroys cancer cells. It is developed based on engineered CAR T-cell technology. It acts by targeting CD19 and CD22.

Autolus Therapeutics overview

Autolus Therapeutics (Autolus), formerly Autolus Therapeutics is a clinical-stage biopharmaceutical company. It offers programmed T cell therapies for the treatment of hematological cancers and solid tumors. Autolus pipeline products includes Obe-cel, AUTO1/22, AUTO5, AUTO6NG, AUTO7 and AUTO8. It has also developed proprietary viral vector and semi-automated cell manufacturing processes, which are used in clinical-stage programs. The company collaborates with leading academic institutions and industry partners to develop and deliver programmed T cell product candidates for cancer patients. Autolus is headquartered in London, Greater London, the UK.

For a complete picture of AUTO-3’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.